<産業資料/調査レポートの題名> 2022年7月15日

遺伝子治療の世界市場:ベクター種類別(ウイルスベクター、非ウイルスベクター)、遺伝子種類別(抗原、サイトカイン、腫瘍抑制因子、自殺、欠乏、成長因子、受容体、その他)、用途別(腫瘍性疾患、希少疾患、心血管疾患、神経疾患、感染症、その他)


◆英文タイトル:Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases): Global Opportunity Analysis and Industry Forecast, 2019–2026

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies

3.3. Top Player Positioning, 2018
3.4. Porter’S Five Forces Analysis
3.5. Market Dynamics

3.5.1. Drivers

3.5.1.1. High Investment For R&D Activities Pertaining To Gene Therapy
3.5.1.2. Increase In Prevalence of Cancer
3.5.1.3. Growth In Awareness Regarding Gene Therapy

3.5.2. Restraints

3.5.2.1. High Cost Associated With Gene Therapies
3.5.2.2. Unwanted Immune Responses

3.5.3. Opportunities

3.5.3.1. Untapped Potential For Emerging Markets

Chapter 4: Gene Therapy Market, By Vector Type

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Viral Vectors

4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Size And Forecast, By Type
4.2.4. Market Size And Forecast, By Country
4.2.5. Adenovirus
4.2.6. Lentivirus
4.2.7. Retrovirus
4.2.8. Adeno-Associated Virus
4.2.9. Herpes Simplex Virus
4.2.10. Poxvirus
4.2.11. Vaccinia Virus
4.2.12. Others

4.3. Non-Viral Techniques

4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Size And Forecast, By Type
4.3.4. Market Size And Forecast, By Country
4.3.5. Naked Plasmid Vector
4.3.6. Gene Gun
4.3.7. Electroporation
4.3.8. Lipofection
4.3.9. Others

Chapter 5: Gene Therapy Market, By Gene Type

5.1. Overview

5.1.1. Market Size And Forecast, Type

5.2. Antigen

5.2.1. Market Size And Forecast
5.2.2. Market Size And Forecast, By Country

5.3. Cytokine

5.3.1. Market Size And Forecast
5.3.2. Market Size And Forecast, By Country

5.4. Tumor Suppressor

5.4.1. Market Size And Forecast, By Region
5.4.2. Market Size And Forecast, By Country

5.5. Suicide Gene

5.5.1. Market Size And Forecast
5.5.2. Market Size And Forecast, By Country

5.6. Deficiency

5.6.1. Market Size And Forecast, By Region
5.6.2. Market Size And Forecast, By Country

5.7. Growth Factors

5.7.1. Market Size And Forecast, By Region
5.7.2. Market Size And Forecast, By Country

5.8. Receptors

5.8.1. Market Size And Forecast, By Region
5.8.2. Market Size And Forecast, By Country

5.9. Others

5.9.1. Market Size And Forecast, By Region
5.9.2. Market Size And Forecast, By Country

Chapter 6: Gene Therapy Market, By Application

6.1. Overview

6.1.1. Market Size And Forecast, By Application

6.2. Oncological Disorders

6.2.1. Market Size And Forecast, By Region
6.2.2. Market Size And Forecast, By Country

6.3. Rare Diseases

6.3.1. Market Size And Forecast, By Region
6.3.2. Market Size And Forecast, By Country

6.4. Cardiovascular Diseases

6.4.1. Market Size And Forecast, By Region
6.4.2. Market Size And Forecast, By Country

6.5. Neurological Disorders

6.5.1. Market Size And Forecast
6.5.2. Market Size And Forecast, By Country

6.6. Infectious Diseases

6.6.1. Market Size And Forecast, By Region
6.6.2. Market Size And Forecast, By Country

6.7. Other Diseases

6.7.1. Market Size And Forecast
6.7.2. Market Size And Forecast, By Country

Chapter 7: Gene Therapy Market, By Region

7.1. Overview

7.1.1. Market Size And Forecast

7.2. North America

7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.3. Market Size And Forecast, By Vector Type
7.2.4. Market Size And Forecast, By Gene Type
7.2.5. Market Size And Forecast, By Application

7.2.5.1. U.S. Market Size And Forecast, By Vector Type
7.2.5.2. U.S. Market Size And Forecast, By Gene Type
7.2.5.3. U.S. Market Size And Forecast, By Application
7.2.5.4. Canada Market Size And Forecast, By Vector Type
7.2.5.5. Canada Market Size And Forecast, By Gene Type
7.2.5.6. Canada Market Size And Forecast, By Application
7.2.5.7. Mexico Market Size And Forecast, By Vector Type
7.2.5.8. Mexico Market Size And Forecast, By Gene Type
7.2.5.9. Mexico Market Size And Forecast, By Application

7.3. Europe

7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.3. Market Size And Forecast, By Vector Type
7.3.4. Market Size And Forecast, By Gene Type
7.3.5. Market Size And Forecast, By Application

7.3.5.1. Germany Market Size And Forecast, By Vector Type
7.3.5.2. Germany Market Size And Forecast, By Gene Type
7.3.5.3. Germany Market Size And Forecast, By Application
7.3.5.4. France Market Size And Forecast, By Vector Type
7.3.5.5. France Market Size And Forecast, By Gene Type
7.3.5.6. France Market Size And Forecast, By Application
7.3.5.7. Uk Market Size And Forecast, By Vector Type
7.3.5.8. Uk Market Size And Forecast, By Gene Type
7.3.5.9. Uk Market Size And Forecast, By Application
7.3.5.10. Italy Market Size And Forecast, By Vector Type
7.3.5.11. Italy Market Size And Forecast, By Gene Type
7.3.5.12. Italy Market Size And Forecast, By Application
7.3.5.13. Spain Market Size And Forecast, By Vector Type
7.3.5.14. Spain Market Size And Forecast, By Gene Type
7.3.5.15. Spain Market Size And Forecast, By Application
7.3.5.16. Rest of Europe Market Size And Forecast, By Vector Type
7.3.5.17. Rest of Europe Market Size And Forecast, By Gene Type
7.3.5.18. Rest of Europe Market Size And Forecast, By Application

7.4. Asia-Pacific

7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.3. Market Size And Forecast, By Vector Type
7.4.4. Market Size And Forecast, By Gene Type
7.4.5. Market Size And Forecast, By Application

7.4.5.1. Japan Market Size And Forecast, By Vector Type
7.4.5.2. Japan Market Size And Forecast, By Gene Type
7.4.5.3. Japan Market Size And Forecast, By Application
7.4.5.4. China Market Size And Forecast, By Vector Type
7.4.5.5. China Market Size And Forecast, By Gene Type
7.4.5.6. China Market Size And Forecast, By Application
7.4.5.7. India Market Size And Forecast, By Vector Type
7.4.5.8. India Market Size And Forecast, By Gene Type
7.4.5.9. India Market Size And Forecast, By Application
7.4.5.10. South Korea Market Size And Forecast, By Vector Type
7.4.5.11. South Korea Market Size And Forecast, By Gene Type
7.4.5.12. South Korea Market Size And Forecast, By Application
7.4.5.13. Rest of Asia-Pacific Market Size And Forecast, By Vector Type
7.4.5.14. Rest of Asia-Pacific Market Size And Forecast, By Gene Type
7.4.5.15. Rest of Asia-Pacific Market Size And Forecast, By Application

7.5. Lamea

7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.3. Market Size And Forecast, By Vector Type
7.5.4. Market Size And Forecast, By Gene Type
7.5.5. Market Size And Forecast, By Application

7.5.5.1. Brazil Market Size And Forecast, By Vector Type
7.5.5.2. Brazil Market Size And Forecast, By Gene Type
7.5.5.3. Brazil Market Size And Forecast, By Application
7.5.5.4. South Africa Market Size And Forecast, By Vector Type
7.5.5.5. South Africa Market Size And Forecast, By Gene Type
7.5.5.6. South Africa Market Size And Forecast, By Application
7.5.5.7. Rest of Lamea Market Size And Forecast, By Vector Type
7.5.5.8. Rest of Lamea Market Size And Forecast, By Gene Type
7.5.5.9. Rest of Lamea Market Size And Forecast, By Application

Chapter 8: Company Profile

8.1. Adaptimmune Therapeutics Plc.

8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves And Developments

8.2. Anchiano Therapeutics Ltd.

8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio

8.3. Achieve Life Sciences, Inc.

8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Key Strategic Moves And Developments

8.4. Adverum Biotechnologies, Inc.

8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Key Strategic Moves And Developments

8.5. Abeona Therapeutics Inc.

8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments

8.6. Applied Genetic Technologies Corporation

8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments

8.7. Arbutus Biopharma Corporation

8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Product Portfolio
8.7.4. Business Performance
8.7.5. Key Strategic Moves And Developments

8.8. Audentes Therapeutics Inc.

8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Product Portfolio
8.8.4. Key Strategic Moves And Developments

8.9. Avexis Inc.

8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Product Portfolio
8.9.4. Key Strategic Moves And Developments

8.10. Bluebird Bio, Inc.

8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves And Developments

8.11. Celgene Corporation

8.11.1. Company Overview
8.11.2. Company Snapshot
8.11.3. Operating Business Segments
8.11.4. Product Portfolio
8.11.5. Business Performance
8.11.6. Key Strategic Moves And Developments

8.12. Crispr Therapeutics Ag

8.12.1. Company Overview
8.12.2. Company Snapshot
8.12.3. Product Portfolio
8.12.4. Business Performance
8.12.5. Key Strategic Moves And Developments

8.13. Editas Medicine, Inc.

8.13.1. Company Overview
8.13.2. Company Snapshot
8.13.3. Operating Business Segments
8.13.4. Product Portfolio
8.13.5. Business Performance
8.13.6. Key Strategic Moves And Developments

8.14. Gilead Sciences, Inc.

8.14.1. Company Overview
8.14.2. Company Snapshot
8.14.3. Operating Business Segments
8.14.4. Product Portfolio
8.14.5. Business Performance
8.14.6. Key Strategic Moves And Developments

8.15. Glaxosmithkline Plc

8.15.1. Company Overview
8.15.2. Company Snapshot
8.15.3. Operating Business Segments
8.15.4. Product Portfolio
8.15.5. Business Performance
8.15.6. Key Strategic Moves And Developments

8.16. Intellia Therapeutics Inc.

8.16.1. Company Overview
8.16.2. Company Snapshot
8.16.3. Operating Business Segments
8.16.4. Product Portfolio
8.16.5. Business Performance
8.16.6. Key Strategic Moves And Developments

8.17. Merck & Co., Inc.

8.17.1. Company Overview
8.17.2. Company Snapshot
8.17.3. Operating Business Segments
8.17.4. Product Portfolio
8.17.5. Business Performance
8.17.6. Key Strategic Moves And Developments

8.18. Novartis Ag

8.18.1. Company Overview
8.18.2. Company Snapshot
8.18.3. Operating Business Segments
8.18.4. Product Portfolio
8.18.5. Business Performance
8.18.6. Key Strategic Moves And Developments

8.19. Regenxbio, Inc.

8.19.1. Company Overview
8.19.2. Company Snapshot
8.19.3. Product Portfolio
8.19.4. Business Performance
8.19.5. Key Strategic Moves And Developments

8.20. Spark Therapeutics, Inc.

8.20.1. Company Overview
8.20.2. Company Snapshot
8.20.3. Operating Business Segments
8.20.4. Product Portfolio
8.20.5. Business Performance
8.20.6. Key Strategic Moves And Developments

8.21. Sangamo Therapeutics, Inc.

8.21.1. Company Overview
8.21.2. Company Snapshot
8.21.3. Operating Business Segments
8.21.4. Product Portfolio
8.21.5. Business Performance
8.21.6. Key Strategic Moves And Developments

8.22. Uniqure N. V.

8.22.1. Company Overview
8.22.2. Company Snapshot
8.22.3. Operation Segments
8.22.4. Product Portfolio
8.22.5. Business Performance
8.22.6. Key Strategic Moves And Developments

8.23. Voyager Therapeutics, Inc.

8.23.1. Company Overview
8.23.2. Company Snapshot
8.23.3. Operating Business Segments
8.23.4. Product Portfolio
8.23.5. Business Performance
8.23.6. Key Strategic Moves And Developments


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark